Rivaroxaban (Xarelto) Gains First FDA Approval for DVT Prevention - Larry Husten - Cardiobrief - Forbes
Links shared publicly online about this topic.
- 178total visits
Rivaroxaban (Xarelto) Gains First FDA Approval for DVT Prevention - Larry Husten - Cardiobrief - Forbes
Rivaroxaban(Xarelto, Janssen) received FDA approval today for the prevention of deep vein thrombosis which may lead to a pulmonary embolism in patients undergoing knee or hip replacement surgery. The drug is a once-daily oral anticoagulant and has been approved for use at a 10 mg dose, once-daily for 35 days [...]
View full resource at blogs.forbes.com
Tags: Circulatory Disorders, Deep Venous Thrombosis, Thrombotic Event, Drug, FDA, Anti-Clotting Medication, Xarelto
Most Recently Shared on July 1, 2011 at 10:22 pm By:
Rivaroxaban (Xarelto) Gains First FDA Approval for DVT Prevention: Rivaroxaban(Xarelto, Janssen) receiv... http://onforb.es/lPaAi7 #drug
Advertisement
